Prostate Cancer Stem Cells


Nowadays, men over 50 are more likely to develop prostate cancer than ever before. Medical treatments for glandular carcinoma are backed by findings from the middle of the 20th century, although they are unlikely to be curative in the near future. The majority of treatments are focused on a target cell that expresses the androgen receptor and is highly proliferative, which constitutes the vast majority of cells in a prostate tumor. However, the observed resistance to the majority of medical therapy is frequently explained by the existence of a cancer vegetative cell that, like normal epithelial stem cells within the prostate, does not express androgen receptor and is relatively inactive. The phenotypic of glandular cancer stem cells resembles that of a basal cell, and cultures produced from malignancies, but not from benign tissues, exhibit a proliferation of RNAs linked with prostate cancer.


 


    Related Conference of Prostate Cancer Stem Cells

    March 13-14, 2025

    2nd International Conference on Drug Discovery and Development

    Prague, Czech Republic
    April 07-08, 2025

    15th World Congress on Chemistry

    Vancouver, Canada
    May 14-15, 2025

    17th International Conference on Clinical Chemistry

    Toronto, Canada
    June 26-27, 2025

    14th World Congress on Chromatography

    Paris, France
    August 18-19, 2025

    14th World Congress on Biopolymers and Biomaterials

    Valencia, Spain
    September 22-23, 2025

    21st European Organic Chemistry Congress

    Dubai, UAE
    October 27-28, 2025

    15th International Chemistry Congress

    London, UK
    November 06-07, 2025

    6th World Expo on Biopolymers and Bioplastics

    Dubai, UAE
    December 08-09, 2025

    5th International Conference on Analytical Chemistry

    Rome, Italy

    Prostate Cancer Stem Cells Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in